GlaxoSmithKline's Anemia Drug Met Primary Endpoint in Five Phase 3 Studies
July 16 2021 - 6:50AM
Dow Jones News
By Cecilia Butini
GlaxoSmithKline PLC said Friday that five Phase 3 studies of a
drug used to treat patients with anemia due to chronic kidney
disease have met their primary efficacy endpoint.
The British pharmaceutical major said the studies evaluated the
efficacy and safety of the drug, named daprodustat, as part of a
Phase 3 program named Ascend. As a primary endpoint, the drug
demonstrated an improvement in hemoglobin levels both in patients
who weren't receiving other treatments and in patients treated with
another standard treatment option, the company said.
GSK said daprodustat is currently only approved in Japan for
patients with renal anemia and that it isn't approved in any other
country.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
July 16, 2021 07:49 ET (11:49 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
